Completed PHASE3 INTERVENTIONAL 3-arm NCT01235234

Trial of CF101 to Treat Patients With Dry Eye Disease

A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Dose-Finding, Parallel-Group Study of the Safety and Efficacy of Daily CF101 Administered Orally in Patients With Moderate-to-Severe Dry Eye Disease

Sponsor: Can-Fite BioPharma

Conditions Keratoconjunctivitis Sicca

Interventions CF101

Updated 7 times since 2017 Last updated: Jun 29, 2022 Started: Jul 31, 2011 Primary completion: Nov 30, 2013 Completion: Dec 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01235234, this PHASE3 trial focuses on Keratoconjunctivitis Sicca and remains completed. Sponsored by Can-Fite BioPharma, it has been updated 7 times since 2011, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jul 2022 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2022 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Jul 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Can-Fite BioPharma

Data source: Can-Fite BioPharma

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Haifa, Israel